The trade group argues CMS exceeded its authority with GLOBE, a Medicare Part B model tying drug rebates to prices in 19 other countries.
News|Articles|January 28, 2026
3 insights from the third set of drugs for Medicare price negotiations
Author(s)Denise Myshko
CMS announced 15 drugs for Medicare price negotiations under the IRA, representing $27 billion in spending and treating conditions such as diabetes, cancer, and autoimmune conditions. Here are three insights on the list from industry experts.
Advertisement
Advertisement
This morning, CMS released the names of the third set of drugs to be negotiated under the Inflation Reduction Act (IRA). The new maximum fair price (MFP) for these 15 products will be announced in November 2026, with implementation in January 2028.
Related to this article
A session at AAO 2026 explained how Medicare, Medicare Advantage and commercial coverage policies differ in ophthalmology, and how practices can document and code to stay compliant
Presenters at AAO 2026 examined hospital eye coverage gaps, workforce strain and how ophthalmology can gain influence within health systems.
Price transparency data on 11 glaucoma surgery codes showed payer class was most consistently tied to price, with Medicaid and self-pay rates lowest.
Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.
Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.
The 2026 American Academy of Ophthalmology Meeting got started today in New Orleans with a mix of celebration and candor about the challenges facing ophthalmology today.
How LLM decision support reshapes dermatology care, helping non-specialists diagnose while navigating trust gaps, ambiguity, and hallucination risks at Fall Clinical Derm.
Advertisement
Advertisement